Search Results - "Arribas, Jr"

Sulfur isotopic composition of hydrothermal precipitates from the Lau back-arc: implications for magmatic contributions to seafloor hydrothermal systems by Herzig, P. M., Hannington, M. D., Arribas Jr, A.

“…The sulfur isotopic composition of sulfides and barite from hydrothermal deposits at the Valu Fa Ridge back-arc spreading center in the southern Lau Basin has…”
Get full text

Submarine gold mineralization near Lihir Island, New Ireland fore-arc, Papua New Guinea by Petersen, Sven, Herzig, Peter M, Hannington, Mark D, Jonasson, Ian R, Arribas, Jr

“…Gold-rich siliceous veins with disseminated polymetallic sulphides and pyritic stockwork mineralization have been recovered from the top of Conical seamount, ∼…”
Get full text

2019 update of the European AIDS Clinical Society Guidelines for treatment of people living with HIV version 10.0 by Ryom, L, Cotter, A, De Miguel, R, Béguelin, C, Podlekareva, D, Arribas, JR, Marzolini, C, Mallon, PGM, Rauch, A, Kirk, O, Molina, JM, Guaraldi, G, Winston, A, Bhagani, S, Cinque, P, Kowalska, JD, Collins, S, Battegay, M, De Miguel Buckley, Rosa, d'Arminio Monforte, Antonella, Bracchi, Margherita, Dedes, Nikos, Horban, Andrzej, Katlama, Christine, Latysheva, Inga, Lundgren, Jens D., McCormack, Sheena, Mussini, Cristina, Pozniak, Anton, Pulido, Federico, Raffi, François, Reiss, Peter, Stellbrink, Hans‐Jürgen, Vasylyev, Marta, Gibbons, Sara, Livio, Françoise, Behrens, Georg, Bower, Mark, Compston, Juliet, De Wit, Stéphane, Fabbri, Leonardo M., Fux, Christoph A., Gisslen, Magnus, Lundgren, Jens D., Martínez, Esteban, Miro, José M., Negredo, Eugenia, Poulter, Neil, Reiss, Peter, Sebastiani, Giada, Berenguer, Juan, Boesecke, Christoph, Bruno, Raffaele, Konov, Svilen, Lacombe, Karine, Mauss, Stefan, Mendão, Luís, Peters, Lars, Puoti, Massimo, Rockstroh, Jürgen K., Ambrosioni, Juan, De Castro, Nathalie, Fätkenheuer, Gerd, Furrer, Hansjakob, Miro, José M., Oprea, Cristiana, Pozniak, Anton, Volny‐Anne, Alain, Rockstroh, Jürgen K., Sullivan, Ann, Martínez, Esteban, Mulcahy, Fiona, d'Arminio Monforte, Antonella, Behrens, Georg, Katlama, Christine, Lundgren, Jens D., Mussini, Cristina, Oprea, Cristiana, Pozniak, Anton, Reiss, Peter, Wensing, Annemarie

“…Background The European AIDS Clinical Society (EACS) Guidelines cover key aspects of HIV management with major updates every two years. Guideline highlights…”
Get full text

Dual Therapy With Darunavir and Ritonavir Plus Lamivudine vs Triple Therapy With Darunavir and Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine or Abacavir and Lamivudine for Maintenance of Human Immunodeficiency Virus Type 1 Viral Suppression: Randomized, Open-Label, Noninferiority DUAL-GESIDA 8014-RIS-EST45 Trial by Pulido, Federico, Ribera, Esteban, Lagarde, María, Pérez-Valero, Ignacio, Palacios, Rosario, Iribarren, José A., Payeras, Antoni, Domingo, Pere, Sanz, José, Cervero, Miguel, Curran, Adrián, Rodríguez-Gómez, Francisco J., Téllez, María J., Ryan, Pablo, Barrufet, Pilar, Knobel, Hernando, Rivero, Antonio, Alejos, Belén, Yllescas, María, Arribas, José R.

“…Our objective was to assess the therapeutic noninferiority of dual therapy with darunavir/ritonavir and lamivudine compared to triple therapy with…”
Get full text

Ritonavir-boosted darunavir combined with raltegravir or tenofovir–emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial by Raffi, François, Prof, Babiker, Abdel G, Prof, Richert, Laura, PhD, Molina, Jean-Michel, Prof, George, Elizabeth C, MSc, Antinori, Andrea, MD, Arribas, Jose R, MD, Grarup, Jesper, DVM, Hudson, Fleur, BA, Schwimmer, Christine, PhD, Saillard, Juliette, MSc, Wallet, Cédrick, MSc, Jansson, Per O, RN, Allavena, Clotilde, MD, Van Leeuwen, Remko, PhD, Delfraissy, Jean-François, Prof, Vella, Stefano, MD, Chêne, Geneviève, Prof, Pozniak, Anton, MD

“…Summary Background Standard first-line antiretroviral therapy for HIV-1 infection includes two nucleoside or nucleotide reverse transcriptase inhibitors…”
Get full text

Tenofovir Disoproxil Fumarate/Emtricitabine and severity of COVID-19 in people with HIV infection by Del Amo, J, Polo, R, Moreno, S, Martínez, E, Cabello, A, Iribarren, JA, Curran, A, Macías, J, Montero, M, Dueñas, C, Mariño, AI, Pérez de la Cámara, S, Díaz, A, Arribas, JR, Jarrín, I, Hernán, MA

Get full text

Efficacy of protease inhibitor monotherapy vs. triple therapy: meta‐analysis of data from 2303 patients in 13 randomized trials by Arribas, JR, Girard, P‐M, Paton, N, Winston, A, Marcelin, A‐G, Elbirt, D, Hill, A, Hadacek, MB

“…Objectives The aim of this analysis was to review the evidence and update a meta‐analysis evaluating the efficacy and safety results from randomized controlled…”
Get full text

The MONET trial: week 144 analysis of the efficacy of darunavir/ritonavir (DRV/r) monotherapy versus DRV/r plus two nucleoside reverse transcriptase inhibitors, for patients with viral load < 50 HIV‐1 RNA copies/mL at baseline by Arribas, JR, Clumeck, N, Nelson, M, Hill, A, Delft, Y, Moecklinghoff, C

“…Background In the MONotherapy in Europe with Tmc114 (MONET) trial, darunavir/ritonavir (DRV/r) monotherapy showed noninferior efficacy vs. two nucleoside…”
Get full text

Bone mineral density and inflammatory and bone biomarkers after darunavir–ritonavir combined with either raltegravir or tenofovir–emtricitabine in antiretroviral-naive adults with HIV-1: a substudy of the NEAT001/ANRS143 randomised trial by Bernardino, Jose I, Dr, Mocroft, Amanda, PhD, Mallon, Patrick W, PhD, Wallet, Cedrick, MSc, Gerstoft, Jan, Prof, Russell, Charlotte, BSc, Reiss, Peter, Prof, Katlama, Christine, MD, De Wit, Stephane, MD, Richert, Laura, PhD, Babiker, Abdel, Prof, Buño, Antonio, MD, Castagna, Antonella, MD, Girard, Pierre-Marie, MD, Chene, Genevieve, Prof, Raffi, Francois, Prof, Arribas, Jose R, MD

“…Summary Background Osteopenia, osteoporosis, and low bone mineral density are frequent in patients with HIV. We assessed the 96 week loss of bone mineral…”
Get full text

Epidemiological trends of HIV/HCV coinfection in Spain, 2015–2019 by Busca, Carmen, Santos, Jesús, Morano, Luis, Artero, Arturo, Rivero‐Román, Antonio, Armiñanzas, Carlos, García, Coral, Galindo, María J., Ferrero, Oscar L., Rodríguez, Carmen, Losa, Juan E., González Garcia, Juan, Fanciulli, C, Pérez‐Latorre, L, Gutiérrez, I, Padilla, B, Arnalich, F, Delgado, A, Hontañón, V, Martín‐Carbonero, ML, Montejano, R, Moreno, V, Navarro, C, Valencia, E, Rivero‐Juárez, A, Brieva, T, Machuca, I, Rivero‐Román, A, Jarrín, I, Vivancos, MJ, Moreno, S, Moreno, A, Pérez‐Elías, MJ, Quereda, C, Torrella, A, Planas, B, Rodrigo, M, Vergas, J, Muñoz, J, Gutiérrez, M, Guardiola, JM, Carmona, MP, Rodríguez‐Arrondo, F, Goenaga, MA, Von Wichmann, MA, Iribarren, JA, Prado‐González, E, Crespo, M, L, Morano, Ruiz, J, Palacios, R, Santos, I, Montero, M, Tasias, M, Cuellar, S, Calabuig, E, López‐Aldeguer, J, Salavert, M, Bisbal, O, De Lagarde, M, Matarranz, M, García, C, Armiñanzas, C, Echevarría, S, Gutiérrez‐Cuadra, M, Fariñas, C, Giner, L, Reus, S, Boix, V, Pampliega, M, Díez, M, Egea, I, Portilla, J, Ibarra, S, López, I, Zubero, Z, Baraia, J, Casas, E, Galindo, MJ, Pérez, L, Oteo, JA, Hervás, R, Muñoz, L, Vargas, M, Castellano, A, Silvariño, R, Orti, AJ, Chamarro, E, Geijo, P, Puerta, T, Cifuentes, C, Vilaró, J, Vegas, A, Campoamor, M, Tuya, MJ, de la Fuente, B, Force, L, Barrufet, P, Gaspar, G, Fernández, I

“…Objectives We assessed the prevalence of anti‐hepatitis C virus (HCV) antibodies and active HCV infection (HCV‐RNA‐positive) in people living with HIV (PLWH)…”
Get full text

Week 48 efficacy and central nervous system analysis of darunavir/ritonavir monotherapy versus darunavir/ritonavir with two nucleoside analogues by Antinori, Andrea, Clarke, Amanda, Svedhem-Johansson, Veronika, Arribas, José R, Arenas-Pinto, Alejandro, Fehr, Jan, Gerstoft, Jan, Horban, Andrzej, Clotet, Bonaventura, Ripamonti, Diego, Girard, Pierre-Marie, Hill, Andrew M, Moecklinghoff, Christiane

“…In previous studies in virologically suppressed patients, protease inhibitor monotherapy has shown trends for more low-level elevations in HIV-1 RNA compared…”
Get full text

Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial by Orkin, Chloe, Molina, Jean-Michel, Negredo, Eugenia, Arribas, José R, Eron, Joseph J, Van Landuyt, Erika, Lathouwers, Erkki, Hufkens, Veerle, Petrovic, Romana, Vanveggel, Simon, Ajana, F, Arribas, JR, Bailey, J, Benson, P, Bhatti, L, Blaxhult, A, Brar, I, Bredeek, UF, Brinson, C, Brunetta, J, Casado, J, Clarke, A, Conway, B, Cotte, L, de Vente, J, DeJesus, E, Dietz, C, Dretler, R, Eron, J, Fehr, J, Felizarta, F, Flamholc, L, Florence, E, Gallant, J, Gasiorowski, J, Gatell, JM, Gathe, J, Gazzard, BG, Girard, P-M, Gisslèn, M, Gutierrez, F, Gutierrez, MDM, Hagins, D, Halota, W, Henn, S, Henry, WK, Horban, A, Huhn, G, Iribarren, JA, Jain, M, Johnson, MA, Katlama, C, Klein, M, Knobel, H, Lucasti, C, Martorell, C, McDonald, C, Mills, A, Molina, J-M, Morales-Ramirez, J, Mounzer, K, Moutschen, M, Murphy, D, Nahass, R, Negredo, E, Olivet, H, Orkin, C, Osiyemi, O, Perez-Valero, I, Pineda, JA, Podzamczer, D, Portilla Sogorb, J, Post, F, Prelutsky, D, Pulido, F, Rachlis, A, Raffi, F, Rashbaum, B, Rauch, A, Rey, D, Reynes, J, Ricart, C, Richmond, G, Rivero, A, Ruane, P, Gil, I Santos, Scarsella, A, Shafran, S, Shalit, P, Shamblaw, D, Slim, J, Stoeckle, M, Tashima, K, Ustianowski, A, Van Wijngaerden, E, Vandercam, B, Walmsley, S, Wilkin, A, Witor, A, Yazdanpanah, Y

“…Simplified regimens with reduced pill burden and fewer side-effects are desirable for people living with HIV. We investigated the efficacy and safety of…”
Get full text

Week 96 efficacy and safety of darunavir/ritonavir monotherapy vs. darunavir/ritonavir with two nucleoside reverse transcriptase inhibitors in the PROTEA trial by Girard, PM, Antinori, A, Arribas, JR, Ripamonti, D, Bicer, C, Netzle‐Sveine, B, Hadacek, B, Moecklinghoff, C

“…Objectives PROTEA is a randomized controlled trial to assess the efficacy and safety of darunavir/ritonavir (DRV/r) monotherapy as an alternative to triple…”
Get full text

Determinants of blood telomere length in antiretroviral treatment‐naïve HIV‐positive participants enrolled in the NEAT 001/ANRS 143 clinical trial by Alejos, B, Stella‐Ascariz, N, Montejano, R, Rodriguez‐Centeno, J, Schwimmer, C, Bernardino, JI, Rodes, B, Esser, S, Goujard, C, Sarmento‐Castro, R, De Miguel, R, Esteban‐Cantos, A, Wallet, C, Raffi, F, Arribas, JR

“…Objectives Our aim was to investigate factors associated with baseline blood telomere length in participants enrolled in NEAT 001/ANRS 143, a randomized,…”
Get full text

HIV/HBV coinfection: temporal trends and patient characteristics, Spain, 2002 to 2018 by Pérez-Latorre, Leire, Berenguer, Juan, Micán, Rafael, Montero, Marta, Cifuentes, Carmen, Puig, Teresa, Sanz, José, Ferrero, Oscar L, De La Fuente, Belén, Rodríguez, Carmen, Reus, Sergio, Hernández-Quero, José, Gaspar, Gabriel, Pérez-Martínez, Laura, García, Coral, Force, Luis, Veloso, Sergio, De Miguel, Marta, Jarrín, Inmaculada, González-García, Juan

“…Background Recent and reliable estimates on the prevalence of coinfection with human immunodeficiency virus (HIV) and hepatitis B virus (HBV) in Europe are…”
Get full text

Week 48 Resistance Analyses of the Once-Daily, Single-Tablet Regimen Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Adults Living with HIV-1 from the Phase III Randomized AMBER and EMERALD Trials by Lathouwers, Erkki, Wong, Eric Y, Brown, Kimberley, Baugh, Bryan, Ghys, Anne, Jezorwski, John, Mohsine, El Ghazi, Van Landuyt, Erika, Opsomer, Magda, De Meyer, Sandra

“…Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg is being investigated in two Phase III trials, AMBER (NCT02431247;…”
Get more information

The effect of protease inhibitor‐based dual antiretroviral regimens on CD4/CD8 ratio during the first year of therapy in ART‐naïve patients with HIV‐infection by Figueroa, MI, Camiro‐Zuñiga, A, Belaunzaran‐Zamudio, PF, Sierra Madero, J, Andrade Villanueva, J, Arribas, JR, Lama, JR, Cecchini, DM, Lopardo, G, Crabtree‐Ramírez, B, Gun, A, Patterson, P, Fink, VI, Sued, OG, Cahn, P

“…Objectives To assess the effect of protease inhibitor (PI)‐based dual therapy on CD4/CD8 ratio during the first year of therapy in antiretroviral therapy…”
Get full text

Evolution of an intrusion-centered hydrothermal system; Far Southeast-Lepanto porphyry and epithermal Cu-Au deposits, Philippines by Hedenquist, Jeffrey W, Arribas, Jr, Reynolds, T. James

“…There are many examples of spatially associated porphyry and epithermal ore deposits; a genetic connection has been suggested for some and argued against for…”
Get full text

How well are we performing the initial assessment of HIV‐positive patients? Results from a multicentre cohort in Spain by del Amo, Julia, Blanco, Jose Luis, Rubio, Rafael, Vidal, Francesc, Berenguer, Juan, Sanz, Nieves, Consuegra Fernández, Irene, Giner, Livia, Gadea, Carmen, Sánchez‐Payá, Jose, del Mar Alonso, María, Hernández, María Inmaculada, Lirola, Ana López, Asensi, Victor, Valle, Eulalia, Pulido, Federico, Bisbal, Otilia, Hernando, Asunción, Lagarde, Maria, Matarranz, Mariano, Arrizabalaga, Julio, Pascual Tomé, Lidia, Bustinduy, Mª Jesús, Umerez, Maitane, Robledano, Catalina, Adsuar, Araceli, García, Elena, Barber, Xavier, Carlos López Bernaldo de Quirós, Juan, Carrero, Ana, Aldamiz‐Echevarría, Teresa, Parras, Francisco Jose, Diez, Cristina, Olona, Montserrat, Alba, Verónica, Montero Alonso, Marta, Calabuig Muñoz, Eva, Cuéllar Tovar, Sandra, Fernández Navarro, Juan, Delgado, A, De Miguel, R, García‐Bujalance, S, Mayoral, M, Montejano, R, Moreno, V, Rua, MG, Sendagorta, E, Oteo, José Antonio, Sanz, Mercedes, Cairó, Mireia, Velli, Pablo, Font, Roser, Xercavins, Mariona, Alonso, Noemí, Ruiz de Alda, María Gracia, Navarro, Gemma, Cervantes, Manuel, Calzado, Sonia, Navarro, Marta, Salas Aparicio, Ana, Moreno, Santiago, Casado, José Luis, Jesús Pérez Elías, María, Gutiérrez, Carolina, Martí, Paloma, Jesús Vivancos, Maria, Cano, Alfredo, García, Federico, Rodríguez, Carmen, Puerta, Teresa, Riera, Melchor, Murillas, Javier, Márquez, Manuel, Viciana, Isabel, López‐Cortés, Luis Fernando, Podzamczer, Daniel, Tiraboschi, Juan, Saumoy, Maria, Olalla, Julián, de la torre, Javier, García de Lomas Guerrero, José María, Martínez, Lorena, Alcaraz, Begoña, Grandal, Marta, Castro, Ángeles, Pedreira, José D., Muñoz, Josefa, Mirena Baraia‐Etxaburu, Josu, Ibarra, Sofía, López, Iñigo, de la Peña, Mireia, Iborra, Asunción, Moreno, Antonio, Ángeles Campillo, Maria, Vidal, Asunción, Amador, Concha, González‐Ruano, Patricia, Mohamed‐Balghata, Mohamed Omar, Moreno, Jose Sanz, Galindo Puerto, Maria Jose

“…Objectives The aim of this study was to evaluate adherence to the recommendations of the Spanish guidelines for the initial assessment of patients with HIV…”
Get full text

Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial by Cahn, Pedro, Sax, Paul E, Squires, Kathleen, Molina, Jean-Michel, Ratanasuwan, Winai, Rojas, Evelyn, Rassool, Mohammed, Vandekerckhove, Linos, Yazdanpanah, Yazdan, Katlama, Christine, Xu, Xia, East, Lilly, Wenning, Larissa, Rawlins, Sandy, Cahn, PE, Roth, N, McMahon, J, Moore, RJ, Smith, D, Clumeck, N, Vanderkerckhove, L, Moutschen, M, Baril, J, Smith, GHR, Walmsley, SL, Perez, C, Katlama, C, Durant, J, Ajana, F, Faetkanheuer, G, Esser, S, Jaeger, H, Degen, O, Bickel, M, Bogner, J, Arasteh, K, Hartl, H, Rojas, EM, Gonzalez, LD, Mejia, CR, Levy, I, Sthoeger, Z, Monforte, A D'Arminio, Di Perri, G, Lazzarin, A, Celesia, BM, Maggiolo, F, Lee, CKC, Mustafa, M, Oyanguren, M, Castillo, RA, Hercilla, L, Echiverri, C, da Cunha, JG Saraiva, Neves, I, Teofilo, E, Nagimova, F, Sotnikov, V, Botes, ME, Kaplan, R, Gatell, JM, Negredo, E, Ortega, E, Aguirrebengoa, K, Antela, A, Calmy, A, Cavassini, M, Lin, HH, Tsai, HC, Changpradub, D, Avihingsanon, A, Kiertiburanakul, S, Ratanasuwan, W, Clarke, A, Ustianowski, A, Winston, A, Johnson, MA, Asmuth, DM, Cade, J, Gallant, JE, Ruane, PJ, Luque, AE, Panther, L, Tashima, KT, Ward, D, Berger, DS, Dietz, CA, Fichtenbaum, C, Mullane, KM, Novak, RM, Crofoot, GE, Hagins, DP, Lewis, ST, McDonald, CK, Sloan, L, Prelutsky, DJ, Ramirez, Santiago, L, Zorrilla, CD, Hsiao, CB

“…Once daily regimens are preferred for HIV-1 treatment, to facilitate adherence and improve quality of life. We compared a new once daily formulation of…”
Get full text